Loading…
AMLX
Amylyx Pharmaceuticals, Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 03237H101
$28.57-1.58%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Amylyx Pharmaceuticals, Inc. (AMLX) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Cambridge, United States and has 136 employees. The company is worth $3.59B. Revenue was $0 in fiscal 2025, down 100.0% from the year before. It reported a net loss of $144.74M. The share price is 30.6% below its 52-week high of $41.14. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $10.66M. In that quarter, 1 of them opened or added to the position and 1 reduced it. Over the last 30 days, company insiders sold $830.9K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $3.59B
- P/E
- —
- Forward P/E
- —
- P/B
- 13.3x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$1.41
- ROE
- -74.73%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.09
- 52-week high
- $41.14
- 52-week low
- $10.83
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +13.6% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $12.08 | $3.78 | $14.72 | $36.95 | |
| P/E | — | — | — | 21.0x | — |
| P/S | 3.8x | — | 3.8x | 2.6x | 110.9x |
| P/B | 3.3x | 4.4x | 2.0x | 2.3x | 7.2x |
| EPS | -$1.53 | -$4.43 | $0.70 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CDNACareDx, Inc. | $69.16 | 33.3x | 8.4x | 0.00% | 29.49% | $3.58B |
| OGNOrganon & Co. | $13.75 | 17.6x | 3.6x | 0.58% | 24.04% | $3.61B |
| LQDALiquidia Corp | $39.69 | 28.0x | 18.1x | 0.00% | 131.82% | $3.55B |
| TLXTelix Pharmaceuticals Ltd | $10.69 |
About the company
- 136
- Cambridge, United States